| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | HLA-DRA1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human HLA-DRA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于HLA-DRA抗体的3篇参考文献示例(注：文献为示例性概括，非真实存在)：
---
1. **文献名称**：*Autoantibodies to HLA-DRA in Systemic Lupus Erythematosus: Pathogenic Role and Clinical Correlation*
**作者**：Chen L, et al.
**摘要**：研究发现系统性红斑狼疮(SLE)患者血清中存在针对HLA-DRA的自身抗体，这些抗体与疾病活动性评分(SLEDAI)显著相关。机制研究表明，抗HLA-DRA抗体可能通过干扰抗原呈递细胞的功能，加剧自身免疫反应。
2. **文献名称**：*HLA-DRA-Specific Antibodies as Biomarkers in Rheumatoid Arthritis*
**作者**：Martinez R, et al.
**摘要**：该研究在类风湿性关节炎(RA)患者中检测到高水平的抗HLA-DRA抗体，其滴度与关节破坏程度和炎症标志物(如CRP)呈正相关。提示HLA-DRA抗体可能作为RA进展的潜在生物标志物。
3. **文献名称**：*Targeting HLA-DRA with Monoclonal Antibodies in Cancer Immunotherapy*
**作者**：Kim S, et al.
**摘要**：研究开发了一种靶向HLA-DRA的单克隆抗体，并在体外实验中证明其可增强T细胞对肿瘤细胞的杀伤作用。结果表明，HLA-DRA抗体可能通过阻断免疫抑制信号通路，增强抗肿瘤免疫应答。
---
**备注**：以上文献为示例性内容，实际研究中请通过PubMed、Web of Science等数据库检索真实文献。若需具体论文，可提供关键词进一步筛选。
The HLA-DRA antibody targets the alpha chain of the HLA-DR heterodimer, a critical component of the human major histocompatibility complex class II (MHC-II) system. HLA-DR molecules are expressed primarily on antigen-presenting cells (e.g., dendritic cells, B cells, macrophages) and play a central role in adaptive immunity by presenting exogenous peptide antigens to CD4+ T cells, initiating immune responses. The HLA-DRA gene encodes the invariant alpha chain, which pairs with a polymorphic beta chain (encoded by HLA-DRB genes) to form the functional HLA-DR complex. Unlike the beta chain, HLA-DRA exhibits limited polymorphism, making it a relatively conserved target for antibodies.
HLA-DRA antibodies are widely used in research to study MHC-II expression, immune cell activation, and antigen presentation dynamics. They are applied in techniques like flow cytometry, immunohistochemistry, and Western blotting to identify HLA-DR-expressing cells in autoimmune diseases, infections, or cancer. For example, elevated HLA-DR expression is associated with autoimmune conditions (e.g., rheumatoid arthritis) or chronic inflammation, while reduced levels may indicate immune evasion in tumors. These antibodies also help investigate genetic or regulatory defects in MHC-II pathways, such as bare lymphocyte syndrome. Commercial HLA-DRA antibodies are typically validated for specificity across human tissues, though cross-reactivity with non-human species requires verification. Their utility extends to monitoring immunotherapies targeting antigen presentation or T cell activation.
×
